Form 4: CRISPR Therapeutics GC Sells Shares After RSU Vesting

CRISPR Therapeutics' General Counsel, James R. Kasinger, acquired 5,500 common shares through RSU vesting and subsequently sold 2,800 shares to cover tax obligations.

Summary

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, acquired 5,500 common shares on March 10, 2026, through the vesting of Restricted Stock Units (RSUs).
• This vesting represents one-quarter of an RSU award granted on March 10, 2023, which originally covered 22,000 common shares.
• On March 11, 2026, Kasinger sold 2,800 common shares at a price of $52.8 per share.
• This sale was a mandatory transaction to cover tax withholding obligations associated with the RSU vesting, as per the Company's RSU Settlement Policy, and was not a discretionary trade.
• Following these transactions, Kasinger directly beneficially owns 87,815 common shares.
• The acquired shares remain subject to a lock-up agreement related to the Issuer's convertible senior notes due 2031.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and tax management, with the vesting itself being a positive for the executive's stake.

Positives

• Vesting of 5,500 Restricted Stock Units (RSUs) for James R. Kasinger, indicating continued compensation and retention of key management.

Negatives

• Sale of 2,800 common shares by a key executive, although it was a non-discretionary sale for tax purposes.

Risks

• Shares acquired from RSU vesting are subject to a lock-up agreement related to the Issuer's convertible senior notes due 2031, which could impact liquidity for the holder.

Future Outlook

The filing indicates a future vesting event for the remaining quarter of the RSU award on March 10, 2027.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vestings and subsequent tax-related sales, are common across the biotechnology and pharmaceutical sectors. These transactions typically reflect pre-scheduled compensation events rather than discretionary trading based on new material information.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting (already accounted for in compensation plans) and a small, non-discretionary sale by an executive.
• Employees: Reinforces the company's compensation structure for executives, potentially signaling stability in executive retention.

Next Steps

• The final quarter of the RSU award (5,500 shares) is scheduled to vest on March 10, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction by an insider related to RSU vesting and tax obligations. It does not provide new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is expected and does not indicate any significant positive or negative shifts for the company's stock.

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Share Sale, James R. Kasinger, General Counsel